Baseline characteristics of responders to milnacipran versus nonresponders to milnacipran (response ≥ 30% improvement in Brief Pain Inventory short form average pain intensity). Values are mean (SD) or median (interquartile range) unless otherwise specified.
| Clinical Characteristics | Nonresponders, n = 23 | Responders, n = 9 |
|---|---|---|
| Age, yrs | 53.4 (13.4) | 55.4 (10.2) |
| RA disease duration, yrs | 9.4 (10.8) | 16.5 (12) |
| Female, n (%) | 20.0 (87.0) | 5 (55.6) |
| White, n (%) | 15 (65.2) | 7 (77.8) |
| RF/CCP-positive, n (%) | 14 (60.9) | 6 (66.7) |
| DMARD use, n (%) | ||
| Nonbiologic | 15 (65.2) | 6 (66.7) |
| Biologic | 10 (43.5) | 4 (44.4) |
| Oral glucocorticoid use, n (%) | 6 (26.1) | 5 (55.6) |
| Meets ACR 2010 criteria, n (%) | 19 (82.6) | 7 (77.8) |
| SJC | 1 (0.0–3.0) | 0 (0.0–1.0) |
| TJC | 6 (3.0–9.0) | 3 (2.0–8.0) |
| CRP | 1.5 (0.4–3.4) | 1.7 (1.1–3.6) |
| DAS28-CRP | 3.6 (2.9–3.8) | 3.1 (2.4–3.6) |
| Tender point count | 7 (3.0–12.0) | 6 (3.0–9.0) |
| HADS anxiety score | 6.1 (5.1) | 5.6 (3.3) |
| HADS depression score | 4.7 (4.3) | 3.1 (2.8) |
| Medical Outcomes Study | ||
| Sleep Problems Index II score | 46.9 (20.5) | 44.1 (19.4) |
| Pain Catastrophizing Scale score | 29.9 (13.6) | 35.6 (14.4) |
RA: rheumatoid arthritis; RF: rheumatoid factor; CCP: cyclic citrullinated peptide; DMARD: disease-modifying antirheumatic drug; ACR: American College of Rheumatology; SJC: swollen joint count; TJC: tender joint count; CRP: C-reactive protein; DAS28: Disease Activity Score at 28 joints; HADS: Hospital Anxiety and Depression Scale.